Bristol-Myers Squibb Reports Fourth Quarter and Full Year Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Alibaba falls on China AI capex report; Citi says selloff is premature
Bristol-Myers Squibb Co. (BMY) PT Lowered to $51 at BMO Capital; 'IO NSCLC Complexity Increases'
February 6, 2018 6:51 AM ESTBMO Capital analyst Alex Arfaei lowered his price target on Bristol-Myers Squibb Co. (NYSE: BMY) to $51.00 (from $52.00) while maintaining a Underperform rating.
Arfaei commented, "When the dust finally settles with the 1L-NSCLC data, we see a fragmented market with Merck's Keytruda... More
Bristol-Myers Squibb (BMY) Tops Q4 EPS by 1c
February 5, 2018 7:02 AM ESTBristol-Myers Squibb (NYSE: BMY) reported Q4 EPS of $0.68, $0.01 better than the analyst estimate of $0.67. Revenue for the quarter came in at $5.4 billion versus the consensus estimate of $5.31 billion.
GUIDANCE:
Bristol-Myers Squibb sees FY2018 EPS of $3.15-$3.30, versus the consensus of... More
